Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours

Clinical Drug Investigation

Volumn 27, Issue 2, 2007, Pages 85-93

  Huse, Daniel M ^a   Von Mehren, Margaret ^b   Lenhart, Gregory ^a   Joensuu, Heikki ^c   Blanke, Charles ^d   Feng, Weiwei ^e   Finkelstein, Stan ^f   Demetri, George ^g  

^a MEDSTAT GROUP   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ARTICLE; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESEARCH; DRUG USE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIFE EXPECTANCY; PALLIATIVE THERAPY; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT PLANNING; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; COST-BENEFIT ANALYSIS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MODELS, ECONOMIC; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33846415876     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727020-00001     Document Type: Article

References (29)

1. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-78
2. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65
3. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-12
4. Sanborn RE, Blanke CD. Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol 2005; 3: 647-57
5. Miettinen M, El-Rifai W, Sobin L, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83
6. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995; 2: 26-31
7. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8
8. Blanke CD. Gastrointestinal stromal tumors: three perspectives on current diagnosis and therapy. Eur J Cancer Suppl 2006; 4: 1-3
9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80
10. van Oosterom AT, Judson IR, Verweij J, et al. Safety and efficacy of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 Suppl. 5: S83-7
11. Clary BM, DeMatteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8: 290-9
12. Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-9
13. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 2005; 9 (25): 1-142
14. Blanke CD, Joensuu H, Demetri GD, et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four year follow-up of a phase II randomized trial [abstract]. J Clin Oncol. 2006; 24 (Suppl.): 18S
15. Chapman JW, Hanna W, Kahn HJ, et al. Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone. Surg Oncol 1996; 5: 265-71
16. Verdecchia A, De Angelis R, Capocaccia R, et al. The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998; 77: 322-9
17. Weston CL, Douglas C, Craft AW, et al. Establishing long-term survival and cure in young patients with Ewing's sarcoma. Br J Cancer 2004; 91: 225-32
18. Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14 (1): 134-42
19. Red Book: Pharmacy's Fundamental Reference, 2005 Edition. Montvale (NJ): Thomson PDR, 2005
20. Physicians' Desk Reference 2005. Montvale (NJ): Thomson PDR, 2005
21. Chang S, Long SR, Kutikova L, et al. Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology 2006; 70: 71-80
22. Bureau of Labor Statistics. Consumer Price Indexes. Washington, DC: US Department of Labor, 2006 [online]. Available from URL: http: //www.bls.gov/cpi/home.htm [Accessed 2007 Jan 2]
23. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-41
24. Edejer TT, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003
25. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302-17
26. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004; 101: 2574-83
27. Manton KG, Stallard E. Chronic disease modeling. New York: Oxford University Press, 1988
28. Demetri G, Mehren VM, Joensuu H, et al. Relation between gastrointestinal stromal tumor (GIST) response to imatinib therapy and long-term survival. Annals Oncology 2006; 17 (Suppl. 9): ix161-ix170
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology [online]. Available from URL: http: //www.nccn.org/professionals/ physician_gls/f_guidelines.asp [Accessed 2007 Jan 2]